Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a 4.24% gain on the day, the stock’s overall momentum and technical indicators suggest a cautious outlook, with a recent downgrade from Hold to Sell by MarketsMOJO underscoring the evolving market sentiment.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting changing market perceptions amid broader sector volatility. Despite robust operational metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of price attractiveness relative to peers and historical averages.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 February 2026, providing investors with the most recent insights into the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd commenced trading on 3 Feb 2026 with a significant gap up, opening 5.98% higher than its previous close. This robust start outpaced the Pharmaceuticals & Biotechnology sector’s gain of 2.66%, signalling a notably positive market response amid a day that saw the stock reach an intraday high of Rs 182.6, an 8.05% increase.

Jagsonpal Pharmaceuticals Ltd has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating, raising concerns about its price attractiveness relative to historical levels and peer benchmarks. Despite a recent uptick in share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest investors should carefully weigh the risks amid a challenging sector backdrop.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.158.5 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.165 today, marking a significant decline amid broader market pressures and company-specific valuation concerns. The stock has underperformed its sector and benchmark indices, reflecting a challenging period for the pharmaceutical firm.

Jagsonpal Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.168.7 on 20 Jan 2026, marking a significant downturn amid a broader market pullback. The stock has underperformed its sector and benchmark indices, reflecting ongoing valuation concerns despite recent profit growth.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.174.5 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific valuation concerns.

Jagsonpal Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.178 on 12 Jan 2026, marking a significant downturn amid broader market weakness and sector underperformance. The stock’s recent trajectory reflects a combination of valuation concerns and relative underperformance against benchmarks.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd has touched a new 52-week low of Rs.181.35 today, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures. The stock’s recent performance reflects a continuation of downward momentum, with notable underperformance relative to its sector and benchmark indices.